[1]
Antipsychotics increase mortality in elderly patients with dementia: http://www.npc.nhs.uk/merec/cns/dementia/merec_extra_no39.php.
[2]
Aricept Tablets - Summary of Product Characteristics (SPC) - (eMC): http://www.medicines.org.uk/emc/medicine/577/SPC/Aricept.
[3]
Bhasin, M. et al. 2007. Cholinesterase inhibitors in dementia with Lewy bodies—a comparative analysis. International Journal of Geriatric Psychiatry. 22, 9 (Sep. 2007), 890–895. DOI:https://doi.org/10.1002/gps.1759.
[4]
British National Formulary: http://www.bnf.org/bnf/index.htm.
[5]
Centre for Medicines Optimisation - MTRAC | Independent Medicines Review | Midlands Therapeutics Review & Advisory Committee | Centre for Medicines Optimisation | Keele University: http://centreformedicinesoptimisation.co.uk/mtrac/.
[6]
Chronic obstructive pulmonary disease: http://cks.nice.org.uk/chronic-obstructive-pulmonary-disease.
[7]
Clinical guidelines, CG42 - Issued: November 2006: http://guidance.nice.org.uk/CG42.
[8]
Commissioners and healthcare professionals - Training videos: http://healthcheck.nhs.uk/commissioners_and_providers/training/training_videos1/.
[9]
Complete Guide to Behavioural and Psychological symptoms of Dementia: http://www.ipa-online.org/.
[10]
CPPE - Centre for Pharmacy Postgraduate Education: https://www.cppe.ac.uk/.
[11]
DH Living well with dementia: a National Dementia Strategy: https://www.gov.uk/government/organisations/department-of-health.
[12]
Ebixa 5mg/pump actuation oral solution, 20mg and 10 mg Tablets and Treatment Initiation Pack - Summary of Product Characteristics (SPC) - (eMC): http://www.medicines.org.uk/EMC/medicine/10175/SPC/rEbxia+5mg+pump+oral+solution%252c+20mg+and+10+mg+tablets+and+Treatment+Initiation+Pack/.
[13]
Electronic Medicines Compendium (eMC): http://www.medicines.org.uk/emc/.
[14]
Electronic Medicines Compendium (eMC): http://www.medicines.org.uk/emc/.
[15]
Electronic Medicines Compendium (eMC): https://www.medicines.org.uk/emc/.
[16]
Evidence Search - Search Engine for Evidence in Health and Social Care: https://www.evidence.nhs.uk/.
[17]
Evidence Search - Search Engine for Evidence in Health and Social Care: https://www.evidence.nhs.uk/.
[18]
Evidence Search - Search Engine for Evidence in Health and Social Care: https://www.evidence.nhs.uk/.
[19]
Exelon - Summary of Product Characteristics (SPC) - (eMC): https://www.medicines.org.uk/emc/search?q=Exelon+.
[20]
GOV.UK: https://www.gov.uk/government/organisations/department-of-health.
[21]
Greene, R.J. and Harris, N.D. 2008. Pathology and therapeutics for pharmacists: a basis for clinical pharmacy practice. Pharmaceutical Press.
[22]
Heart failure - chronic: http://cks.nice.org.uk/heart-failure-chronic.
[23]
Hubley, J. et al. 2013. Practical health promotion. Polity Press.
[24]
Kavirajan, H. and Schneider, L.S. 2007. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. The Lancet Neurology. 6, 9 (Sep. 2007), 782–792. DOI:https://doi.org/10.1016/S1474-4422(07)70195-3.
[25]
Kumar, P.J. and Clark, M.L. 2012. Kumar & Clark’s clinical medicine. Saunders Elsevier.
[26]
Laverack, G. 2007. Health promotion practice: building empowered communities. Open University Press.
[27]
Macdowall, W. et al. 2006. Health promotion practice. Open University Press.
[28]
Maher, A.R. et al. 2011. Efficacy and Comparative Effectiveness of Atypical Antipsychotic Medications for Off-Label Uses in Adults. JAMA. 306, 12 (Sep. 2011). DOI:https://doi.org/10.1001/jama.2011.1360.
[29]
Maher, A.R. 2011. Efficacy and Comparative Effectiveness of Atypical Antipsychotic Medications for Off-Label Uses in AdultsA Systematic Review and Meta-analysis. JAMA: The Journal of the American Medical Association. 306, 12 (Sep. 2011). DOI:https://doi.org/10.1001/jama.2011.1360.
[30]
Map of Medicine | Home: http://www.mapofmedicine.com/.
[31]
Martinón-Torres, G. et al. 2004. Trazodone for agitation in dementia. Cochrane Database of Systematic Reviews. (Jul. 2004). DOI:https://doi.org/10.1002/14651858.CD004990.
[32]
Medicines Information - Evidence Search - Search Engine for Evidence in Health and Social Care: https://www.evidence.nhs.uk/.
[33]
Miller, W.R. and Rollnick, S. 2013. Motivational interviewing: helping people change. Guilford Press.
[34]
National Institute for Health and Care Excellence: http://www.nice.org.uk/.
[35]
NHS Health Check - NHS Choices: http://www.nhs.uk/Conditions/nhs-health-check/Pages/NHS-Health-Check.aspx.
[36]
NICE Clinical Knowledge Summaries (CKS): http://cks.nice.org.uk/.
[37]
NPC | National Prescribing Centre: https://www.guidelinesinpractice.co.uk.
[38]
NPC | National Prescribing Centre: https://www.guidelinesinpractice.co.uk.
[39]
Optimising treatment and care for behavioural and psychological symptoms of dementia: A best practice guide: https://www.alzheimers.org.uk/bpsdguide.
[40]
Pierre N. Tariot, M.D.; Rosemary Erb, R.N., B.S.N.; Carol Ann Podgorski, Ph.D.; Christopher Cox, Ph.D.; Shirish Patel, M.D.; Laura Jakimovich, M.S., R.N.; Carrie Irvine, B.A. 1998. Efficacy and Tolerability of Carbamazepine for Agitation and Aggression in Dementia. PsychiatryOnline | American Journal of Psychiatry | Efficacy and Tolerability of Carbamazepine for Agitation and Aggression in Dementia. 155, 1 (1998), 54–61. DOI:https://doi.org/10.1176/ajp.155.1.54.
[41]
Prochaska, J.O. et al. 1994. Changing for good. William Morrow.
[42]
Reminyl Tablets - Summary of Product Characteristics (SPC) - (eMC): .
[43]
Risperdal Tablets, Liquid & Quicklet - Summary of Product Characteristics (SPC) - (eMC): http://www.medicines.org.uk/emc/document.aspx?documentid=12818&docType=SPC.
[44]
Rollnick, S. et al. 1999. Health behavior change: a guide for practitioners. Churchill Livingstone.
[45]
Rollnick, S. et al. 2008. Motivational interviewing in health care: helping patients change behavior. Guilford Press.
[46]
Royal Pharmaceutical Society (RPS): http://www.rpharms.com/home/home.asp.
[47]
Scottish Intercollegiate Guidelines Network (SIGN): http://www.sign.ac.uk/.
[48]
Sube Banerjee 12AD. The use of antipsychotic medication for people with dementia: Time for action. A report for the Minister of State for Care Services.
[49]
TA217 Alzheimer’s disease - donepezil, galantamine, rivastigmine and memantine: guidance (MS Word format): http://guidance.nice.org.uk/TA217/Guidance/doc/English.
[50]
Treatment protocol by NHS Medway: Treatment of  Behaviour That Challenges: http://www.kmpt.nhs.uk/policies.
[51]
Waldemar, G. et al. 2008. Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer’s disease. International Journal of Geriatric Psychiatry. 23, 9 (Sep. 2008), 979–981. DOI:https://doi.org/10.1002/gps.1979.
[52]
Walker, R. and Whittlesea, C. 2012. Clinical pharmacy and therapeutics. Churchill Livingstone.
[53]
Warner, J. and Smith, T. The rise and fall of antipsychotic prescribing in dementia. Where do we go from here? The rise and fall of antipsychotic prescribing in dementia. 14, 2, 24–27.
[54]
Coeliac disease: recognition, assessment and management  | Guidance and guidelines | NICE.
[55]
Medicines Use Review and Prescription Intervention service.
[56]
Service specification - New Medicine Service (NMS).